Ranked #1,638 of 8,699 institutional investors
Sofinnova Investments, Inc.
Menlo Park, CA
$1.78B
US stock portfolio at live prices · today +$2.2M (+0.12%)
Market closed. Prices as of Nov 20, 8:11 AM ET
- Value at quarter end (Q3 2026)
- $2.03B
- Change from Q2 2026
- +$154.7M (+8.26%)
- Positions
- 54 · 12 new, 6 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: call options on $46.0M of stock, put options on $229M. $217M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesNTRA 25.3%GMAB 12.6%VERA 4.20%SPTX 3.67%RYTM 3.51%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| NTRA Natera, Inc. | 1,550,280 | $449M | 25.3% | Unchanged |
| GMAB Genmab A/S | 4,349,551 | $223M | 12.6% | Added +8% |
| VERA Vera Therapeutics, Inc. | 2,793,987 | $74.7M | 4.20% | Unchanged |
| SPTX Seaport Therapeutics, Inc. | 3,564,871 | $65.3M | 3.67% | Unchanged |
| RYTM Rhythm Pharmaceuticals, Inc. | 534,538 | $62.4M | 3.51% | Added +31% |
| AXSM Axsome Therapeutics, Inc. | 445,906 | $60.5M | 3.40% | Added +178% |
| LLY Eli Lilly and Company | 43,777 | $59.1M | 3.33% | New |
| RAPP Rapport Therapeutics, Inc. | 1,904,408 | $44.9M | 2.53% | Unchanged |
| DYN Dyne Therapeutics, Inc. | 2,511,006 | $40.3M | 2.26% | Added +51% |
| RARE Ultragenyx Pharmaceutical Inc. | 1,753,703 | $30.2M | 1.70% | Added +2% |
| NVS Novartis AG | 196,700 | $29.7M | 1.67% | New |
| INBX Inhibrx Biosciences, Inc. | 391,621 | $29.1M | 1.64% | Added +29% |
| IMNM Immunome, Inc. | 1,627,469 | $27.0M | 1.52% | Reduced −5% |
| BMRN BioMarin Pharmaceutical Inc. | 432,695 | $26.6M | 1.50% | Added +21% |
| IDYA IDEAYA Biosciences, Inc. | 946,340 | $24.8M | 1.39% | Added +2% |
| ABT Abbott Laboratories | 207,000 | $21.5M | 1.21% | Added +68% |
| UTHR United Therapeutics Corporation | 36,491 | $20.4M | 1.15% | Reduced −52% |
| IDXX IDEXX Laboratories, Inc. | 29,145 | $20.1M | 1.13% | New |
| BMY Bristol-Myers Squibb Company | 329,967 | $19.3M | 1.08% | Reduced −62% |
| AVBP ArriVent BioPharma, Inc. | 1,696,752 | $19.1M | 1.07% | Unchanged |
| MANE Veradermics Inc | 144,054 | $17.9M | 1.01% | Reduced −3% |
| IRON Disc Medicine, Inc. | 231,628 | $17.6M | 0.99% | Added +58% |
| TRAX First Tracks Biotherapeutics, Inc. | 383,588 | $17.1M | 0.96% | Reduced −32% |
| ALNY Alnylam Pharmaceuticals, Inc. | 112,879 | $16.7M | 0.94% | New |
| EWTX Edgewise Therapeutics, Inc. | 396,598 | $16.3M | 0.92% | Added +4% |
| ANAB AnaptysBio, Inc. | 330,396 | $15.7M | 0.88% | Reduced −33% |
| BIIB Biogen Inc. | 63,002 | $15.6M | 0.88% | New |
| BIOA BioAge Labs, Inc. | 2,293,788 | $10.8M | 0.61% | Unchanged |
| DSGN Design Therapeutics, Inc. | 1,144,827 | $10.7M | 0.60% | Added +32% |
| DFTX Definium Therapeutics, Inc. | 339,018 | $10.0M | 0.56% | Added +32% |
| RCUS Arcus Biosciences, Inc. | 626,178 | $9.9M | 0.56% | Reduced −34% |
| ERAS Erasca, Inc. | 677,041 | $9.6M | 0.54% | New |
| TARS Tarsus Pharmaceuticals, Inc. | 110,108 | $8.6M | 0.48% | New |
| NRIX Nurix Therapeutics, Inc. | 523,673 | $7.1M | 0.40% | Unchanged |
| NKTR Nektar Therapeutics | 217,963 | $7.1M | 0.40% | Reduced −54% |
| SLN Silence Therapeutics plc | 211,802 | $4.2M | 0.24% | New |
| MIRM Mirum Pharmaceuticals, Inc. | 19,450 | $1.9M | 0.10% | Reduced −30% |
| SVRA Savara Inc. | 356,224 | $1.9M | 0.10% | Reduced −2% |
| SEPN Septerna, Inc. | 46,217 | $1.8M | 0.10% | Reduced −3% |
| JBIO Jade Biosciences, Inc. | 107,391 | $1.6M | <0.1% | Unchanged |
| SGMT Sagimet Biosciences Inc. | 162,380 | $1.6M | <0.1% | Reduced −3% |
| NXTC NextCure, Inc. | 222,654 | $1.5M | <0.1% | Unchanged |
| PAHC Phibro Animal Health Corporation | 43,216 | $1.5M | <0.1% | New |
| PRAX Praxis Precision Medicines, Inc. | 3,703 | $1.2M | <0.1% | Reduced −43% |
| OKUR OnKure Therapeutics, Inc. | 312,553 | $863K | <0.1% | Reduced −3% |
| IVA Inventiva S.A. | 209,500 | $723K | <0.1% | New |
| BOLT Bolt Biotherapeutics, Inc. | 137,721 | $697K | <0.1% | Unchanged |
| ABSI Absci Corporation | 80,817 | $659K | <0.1% | Reduced −76% |
| TYRA Tyra Biosciences, Inc. | 31,407 | $620K | <0.1% | Reduced −3% |
| AKTS Aktis Oncology, Inc. | 31,605 | $518K | <0.1% | Reduced −3% |
| WVE Wave Life Sciences, Inc. | 184,825 | $503K | <0.1% | Reduced −2% |
| IBIO iBio, Inc. | 371,700 | $298K | <0.1% | New |
| LSTA Lisata Therapeutics, Inc. | 156,460 | $142K | <0.1% | New |
| IMA ImageneBio, Inc. | 31,884 | $127K | <0.1% | Unchanged |